{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:43:24Z","timestamp":1784900604581,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Surgery remains the mainstay of treatment for advanced gastric cancer, but in recent years perioperative chemotherapy has been administered in an attempt to improve treatment results. The Cancer Genome Atlas (TCGA) has illuminated the molecular landscape of gastric cancer. However, genomic changes before and after perioperative chemotherapy and the associated effects on treatment resistance remain unclear. This study aimed to clarify genomic change in gastric cancers treated with perioperative chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Of the 532 patients who underwent gastrectomy for gastric cancer between January 2015 and December 2020, this study included eight patients who received neoadjuvant chemotherapy (NAC). We collected biopsy samples before NAC and surgical samples after NAC. Recurrent tumor biopsy samples after adjuvant chemotherapy were also collected in two cases. DNA and RNA were extracted from these samples and analyzed by next-generation sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most of the oncogenic mutations found before NAC (\n                      <jats:italic>TP53<\/jats:italic>\n                      ,\n                      <jats:italic>CDH1<\/jats:italic>\n                      ,\n                      <jats:italic>KRAS<\/jats:italic>\n                      ,\n                      <jats:italic>PIK3CA<\/jats:italic>\n                      ,\n                      <jats:italic>RNF43<\/jats:italic>\n                      , and\n                      <jats:italic>SMAD4<\/jats:italic>\n                      ) were also found in the post-NAC surgical sample. Several gene mutations with low allele frequency were lost or gained. In the recurrent biopsy samples, gene mutations shared before NAC and after NAC were also detected. In addition, some gene mutations were acquired as new mutations following surgery. Gene expression analysis showed genes related to the MAPK signaling pathway were overexpressed in the group without recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most of the oncogenic mutations were maintained throughout perioperative chemotherapy and remained in recurrent tumors. The development of drugs that affect oncogenic mutations during perioperative chemotherapy is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-025-04425-6","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:28:33Z","timestamp":1764073713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of perioperative chemotherapy-mediated genomic changes in gastric cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Ko","family":"Ikegame","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Hada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiya","family":"Yasutome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Iimuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Amemiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Hirotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"3","key":"4425_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4425_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10120-021-01178-5","volume":"24","author":"S Suzuki","year":"2021","unstructured":"Suzuki S, Takahashi A, Ishikawa T, Akazawa K, Katai H, Isobe Y, et al. Surgically treated gastric cancer in Japan: 2011 annual report of the national clinical database gastric cancer registry. Gastric Cancer. 2021;24(3):545\u201366.","journal-title":"Gastric Cancer"},{"issue":"1","key":"4425_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"10184","key":"4425_CR4","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"key":"4425_CR5","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer A. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"issue":"7517","key":"4425_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Comprehensive molecular characterization of gastric adenocarcinoma","year":"2014","unstructured":"Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"5","key":"4425_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449\u201356.","journal-title":"Nat Med"},{"issue":"2","key":"4425_CR8","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4425_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mgg3.120","volume":"3","author":"Y Hirotsu","year":"2015","unstructured":"Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med. 2015;3(2):121\u20139.","journal-title":"Mol Genet Genomic Med"},{"key":"4425_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cca.2018.11.002","volume":"488","author":"K Amemiya","year":"2019","unstructured":"Amemiya K, Hirotsu Y, Oyama T, Omata M. Relationship between formalin reagent and success rate of targeted sequencing analysis using formalin fixed paraffin embedded tissues. Clin Chim Acta. 2019;488:129\u201334.","journal-title":"Clin Chim Acta"},{"issue":"26","key":"4425_CR11","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, et al. Prodigy: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39(26):2903\u201313.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4425_CR12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081\u201392.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4425_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00595-019-01896-5","volume":"50","author":"M Tokunaga","year":"2020","unstructured":"Tokunaga M, Sato Y, Nakagawa M, Aburatani T, Matsuyama T, Nakajima Y, et al. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg Today. 2020;50(1):30\u20137.","journal-title":"Surg Today"},{"issue":"9","key":"4425_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay4211","volume":"6","author":"Z Li","year":"2020","unstructured":"Li Z, Gao X, Peng X, May Chen MJ, Li Z, Wei B, et al. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. Sci Adv. 2020;6(9):eaay4211.","journal-title":"Sci Adv"},{"issue":"11","key":"4425_CR15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s13258-022-01248-7","volume":"44","author":"YJ Huh","year":"2022","unstructured":"Huh YJ, Cho SY, Cho MS, Lee KE, Lee JH. Comparative analysis of cancer gene mutations using targeted sequencing in matched primary and recurrent gastric cancers after chemotherapy. Genes Genomics. 2022;44(11):1425\u201335.","journal-title":"Genes Genomics"},{"issue":"10","key":"4425_CR16","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202215705","volume":"14","author":"T Seidlitz","year":"2022","unstructured":"Seidlitz T, Schm\u00e4che T, Garc\u03afa F, Lee JH, Qin N, Kochall S, et al. Sensitivity towards HDAC inhibition is associated with RTK\/MAPK pathway activation in gastric cancer. EMBO Mol Med. 2022;14(10):e15705.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"4425_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-019-1246-4","volume":"36","author":"Y Hirotsu","year":"2019","unstructured":"Hirotsu Y, Mochizuki H, Amemiya K, Ohyama H, Yoshimura D, Amano H, et al. Deficiency of mismatch repair genes is less frequently observed in signet ring cell compared with non-signet ring cell gastric cancer. Med Oncol. 2019;36(3):23.","journal-title":"Med Oncol"},{"issue":"1","key":"4425_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-019-1094-x","volume":"19","author":"H Ohyama","year":"2019","unstructured":"Ohyama H, Yoshimura D, Hirotsu Y, Amemiya K, Amano H, Miura Y, et al. Rapidly declining trend of signet ring cell cancer of the stomach may parallel the infection rate of Helicobacter pylori. BMC Gastroenterol. 2019;19(1):178.","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"4425_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00535-019-01547-z","volume":"54","author":"S Takaoka","year":"2019","unstructured":"Takaoka S, Hirotsu Y, Ohyama H, Mochizuki H, Amemiya K, Oyama T, et al. Molecular subtype switching in early-stage gastric cancers with multiple occurrences. J Gastroenterol. 2019;54(8):674\u201386.","journal-title":"J Gastroenterol"},{"issue":"2","key":"4425_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10549-022-06731-z","volume":"196","author":"H Watanabe","year":"2022","unstructured":"Watanabe H, Nakagomi H, Hirotsu Y, Amemiya K, Mochizuki H, Inoue M, et al. TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer. Breast Cancer Res Treat. 2022;196(2):255\u201366.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4425_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/annonc\/mdv508","volume":"27","author":"Y Kuboki","year":"2016","unstructured":"Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, et al. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. Ann Oncol. 2016;27(1):127\u201333.","journal-title":"Ann Oncol"},{"issue":"6280","key":"4425_CR22","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139.","journal-title":"Science"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04425-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04425-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04425-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:54:10Z","timestamp":1781618050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04425-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4425"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04425-6","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"4 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients. This study was approved by the Institutional Review Board at Yamanashi Central Hospital (Approval No. G-2018-4).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"832"}}